Reply: Comment on ‘Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal-antibody therapy for RAS wild-type metastatic colorectal cancer'

Detalles Bibliográficos
Autores principales: Rowland, Andrew, Dias, Mafalda M, Wiese, Michael D, Kichenadasse, Ganessan, McKinnon, Ross A, Karapetis, Christos S, Sorich, Michael J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705877/
https://www.ncbi.nlm.nih.gov/pubmed/26355231
http://dx.doi.org/10.1038/bjc.2015.325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705877/
https://www.ncbi.nlm.nih.gov/pubmed/26355231
http://dx.doi.org/10.1038/bjc.2015.325

Ejemplares similares